



Resonance Health Ltd
ASX / Media Release
5 April 2013

HepaFat-Scan® Update

Resonance Health has submitted additional information on HepaFat-Scan® requested by the US Food and Drug Administration (FDA). The Company is hopeful that the FDA will clear HepaFat-Scan® for marketing in the next four to six weeks.

This presents an exciting new business opportunity for Resonance Health as fatty liver disease has become a significant health care burden in most Western countries.

The Gastroenterological Society of Australia has recently released a report looking at the economic cost and health burden of liver disease in Australia. The most prevalent liver disease was found to be non-alcoholic fatty liver disease (NAFLD) which affects an estimated 5.5 million Australians, including 40% of all adults aged 50 years and above. Major risk factors are obesity, high cholesterol and type 2 diabetes. Non-alcoholic fatty liver disease is currently diagnosed through liver blood tests and requires imaging of the liver to detect excess fat. HepaFat-Scan® provides a more quantifiable and accurate imaging assessment of the amount of fat in the liver than other tests currently available.

Due to the increasing prevalence of fatty liver disease, pharmaceutical companies are working to develop new drug therapies to address this health care issue. HepaFat-Scan® provides a suitable diagnostic test to be used in clinical trials to measure the efficacy of new drugs under development.

By Order of the Board

Resonance Health Limited

For further information please contact Resonance Health:

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Naomi Haydari
Company Secretary
T: +61 8 9286 5300
E: naomih@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.